NURO was streamed live on TechCrunch from San Francisco for INDIE BIO Demo Day 2018. After almost 5 months, 14 companies graduated from what is considered the leading Life Science's Accelerator in the world. NURO, not only graduated with only its Founder and CEO on-location for the entire duration of the program, but also managed to grab the last famous KILLER OF THE WEEK Award with an incredible live demonstration of NUOS for the first time.

Google's interests in healthcare and incredible tools to assist human kind are in harmony with both our own technological developments and our core philosophy. We are proud to be selected with 11 other firms for this incredible accelerator and very much look forward to establishing a strong and fruitful collaboration with Google, the Google developers and industry mentors.

Fast Company spotlights NURO's NUOS as a transformative leap in brain–computer interface technology, enabling completely locked-in or voiceless patients to communicate and control digital systems using only neurological signals. This "neural operating system" bypasses the need for surgery or implants, relying on real-time multimodal signal processing. NUOS officially positions NURO as a category-defining leader in the emerging neural interface market.

An in-depth coverage was done by the highly-respected tech journalist, Erin Brodwin, on what NURO had accomplished in 2018 during our Silicon Valley residency. This was an important new validation for our team and a confirmation that our work was starting to be valuable to patients in need and certainly noticeable to the rest of the World and other significant efforts in the field of neurotechnology.

CTRL-Labs was a firm specializing in neurotechnology, specifically, an enhanced electromyography system. Their team specialized in processing muscular signals from your wrist and was bought out by Meta for what is reported to be one billion dollars!

The Royal Society is a Fellowship of many of the World's most eminent scientists and is the oldest scientific academy in existence. In this important publication, The Royal Society takes a deeper look into neural and brain-computer interfaces.

Did you know that over $19 billion has been invested in Neurotech companies in the last 20 years ? This and much more can be found in this reference article about our industry. One can see an overview of the global NeuroTech landscape in 2020 with over 200 companies worldwide working on different areas such as NeuroModulation, NeuroImaging, NeuroPharmacology and ofcourse Brain Computer Interfaces in which NURO fits with 12 other firms.

MASS DEVICE covers NURO with its latest patent issuance, covering our first-in-class, multimodal, non-surgical neurotechnology for the early detection and continuous monitoring of neurological disease by Artificial Intelligence in a portable helmet form factor.

Diagnosed with ALS at 15 and fully locked-in by 17, a Chicago teen was left without communication options despite access to top U.S. hospitals. Within 24 hours of a request from The Mount Sinai Health System, NURO deployed NUOS, enabling her to communicate and access entertainment independently—proving both the scalability and immediate transformative impact of our platform.

NURO launches a brand new surgery-free keyboard controllable multimodally and wirelessly by thought or intent. This new innovation named KOMPOS is offered to all users of the NUOS neurotechnology as a free update and opens a wide door for enhanced communication from incapacitated patients unable to use classic systems like Eye Gaze.

NURO has launched KOMPOS II, a surgery-free neurological keyboard that users can control purely through brain signals. Featuring 44 new keys, KOMPOS II delivers richer input functionality to support communication for users with severe physical limitations. Released as another free update for NUOS users, KOMPOS II enhances NURO's assistive technology suite by boosting performance without added calibration or training, while strengthening NURO as a leader in scalable, non-invasive neural interfaces.

NURO is proud to announce its selection at the 2025 Global Medtech Showcase. Chosen from a competitive field of over 100 international applicants, NURO will spotlight its groundbreaking non-invasive Neurotechnology product lines to an international panel of experts in the medtech and venture capital sectors.

The NURO team has reached an unprecedented milestone with individuals who have been clinically assessed as dead and eventually resuscitated with severe diffuse brain injuries. These patients, previously deemed to be unreachable and vegetative at best, have now regained the ability to communicate through NUOS 3, the flagship non-surgical neurotechnology platform from NURO, despite complete entrapment.

NURO is proud to announce a major leap forward in Neurotechnology with the expanded capabilities of its brand new GRIDLY — the first system in the world enabling wireless control of both Microsoft and Apple software by thought alone, without any brain surgery, implants, or external eye-tracking.

NURO is proud to announce the launch of MENTIS, a brand new product line delivering real-time data across various mental states for cognitive performance, operational decision-making, and human optimization.

In a world-first, NURO has demonstrated that a completely locked-in patient suffering from a severe Anoxic Brain Injury can now control Smartbox's GRID 3 eye-tracking software purely by neurological signals, wirelessly, revolutionizing the use of a classic clinical methodology for patients unable to track with their eyes.